GLP‑1 drugs like semaglutide, originally for diabetes and weight loss, also act in the brain and may help protect against Alzheimer’s and Parkinson’s disease. Animal studies show they reduce brain inflammation and improve cell energy, while early human trials give mixed results—some cognitive hints in Alzheimer’s and clearer motor benefits in Parkinson’s. Big phase‑3 studies on semaglutide are now underway, so the idea looks promising but isn’t ready for a home‑grown protocol yet.
C Palmer. Ryan R; Telang. Sagar S SS; Kistler. Natalie M NM; Mayfield. Cory K CK; Hong. Kurt K; Guce...
A study of 83 people who kept taking GLP‑1 drugs like semaglutide before hip or knee replacement surgery found almost no breathing problems during the operation. Only one person, who had taken a higher dose just five days before surgery, had a full stomach that needed to be emptied, and overall complication rates were low.
The paper says that a drug called semaglutide, which is already used for weight loss, may also help people with a type of heart failure called HFpEF, especially when it’s linked to obesity. It improves how well patients can exercise and reduces symptoms, adding to the benefits seen with other drugs like SGLT2 inhibitors. This could be useful for people looking to boost heart health while losing weight, but it still needs a doctor’s oversight.
Studies looked at whether GLP‑1 drugs like semaglutide can help people drink less or feel less craving. The small clinical trials didn’t show a clear drop in how much people drank or their cravings, though semaglutide hinted at a small craving benefit. Big real‑world data sets did show about a 30‑40% lower chance of alcohol‑related problems for people on these drugs. More big trials are needed to be sure.
A quick look at studies shows that GLP‑1 drugs like semaglutide can help lower binge‑eating episodes and may ease food cravings, while overall eating habits usually stay the same or get a bit better. There aren’t many reports of new eating‑disorder problems, but the data are still limited.
Ng. Mitchell K MK; Mastrokostas. Paul G PG; Rodriguez. Ariel N AN; Razi. Abigail A; Mastrokostas. Le...
People with diabetes who took semaglutide before a single-level lower back fusion surgery were less likely to be readmitted to the hospital within 90 days and spent less on post‑surgery care, while not having more complications than those who didn’t take the drug.
Brown. Avery A; Patel. Suhani S SS; Li. Elizabeth E; Vu. Alexander Hien AH; Somoza. Eduardo E; Chen....
In a large U.S. study of obese, type‑2 diabetic patients on Medicare or Medicaid, bariatric surgery caused about 23% body‑weight loss after three years, while weekly semaglutide or tirzepatide only produced roughly 2‑3% loss, even when taken continuously for a year. The surgery group was younger and more often female and Hispanic, but after adjusting for these differences the weight‑loss advantage remained clear.
The study looks at the fat around the heart (epicardial fat) and how it gets inflamed, which can worsen heart disease. It shows that the heart fat has receptors for GLP‑1 and GIP drugs like semaglutide, meaning these drugs can directly affect this fat. Triggering those receptors might help the fat remodel in a healthier way, potentially lowering heart risk, but the idea is still being explored.
Rai. Abigail A; Kolli. Mahesh M; Singh. Gaurav Pratap GP; Li Cai. Chao Yuan CY; Balaji. Hariharasudh...
A big analysis of many trials shows that GLP‑1 drugs like semaglutide lower heart attacks, strokes and kidney damage in people with type 2 diabetes. Semaglutide works well, but another drug (efpeglenatide) looked a bit better in the data. Overall, the class of GLP‑1 drugs is cardio‑renal protective.
Zahir. Ali A; Collins. David D; Ip. Seyvonne S; Samghabadi. Peyman P; Douglas. Vanja C VC; LaHue. Sa...
A 37‑year‑old woman on semaglutide lost weight quickly and then developed serious nerve and brain problems because she became deficient in vitamins B12 and thiamine. Even though she got B12 supplements, her symptoms got worse, leading to a diagnosis of Wernicke’s encephalopathy and a nerve disorder linked to rapid diabetes treatment changes. The report warns that fast weight loss from GLP‑1 drugs can cause dangerous neurological issues, especially if vitamin levels aren’t watched closely.
Tongta. Sujitra S; Sungkaworn. Titiwat T; Pathomthongtaweechai. Nutthapoom N
This review says that drugs like semaglutide, already used for diabetes and weight loss, may also help reduce binge‑eating episodes and cravings by acting on brain areas that control hunger and reward. Early human studies are small but show fewer binge episodes and better symptom scores.
Liekens. Lisa L; Kaïret. Koen K; Elst. Elisabeth F EF
A teenage girl with atypical anorexia nervosa took semaglutide, a weight‑loss drug, and her eating disorder got worse, leading to serious heart problems and a hospital stay. Even after stopping the drug, she kept losing weight and later had a panic attack when she gained a little weight. The case shows that semaglutide can worsen mental health issues in people already prone to eating disorders, especially young people.
Zaitoon. Hussein H; Wauters. Aimee D AD; Rodriguez. Luisa M LM; Lynch. Jane L JL
In teens, semaglutide (a GLP‑1 drug) reliably cuts weight and BMI, but it also drops some muscle and may affect bone if you don’t keep up with strength training and enough protein. Side effects are mainly stomach‑related, similar to adults, and we still don’t know how it impacts growth or puberty long‑term. So it works, but you need a careful plan to protect musculoskeletal health and nutrition.
Hammad. Muhammed A M MAM; Quesada. Sophia G SG; Belczyk. Aimee L AL; Ghoniem. Gamal M GM
A study of almost 2,000 non‑diabetic adults who got Botox for an overactive bladder found that those who were also taking the weight‑loss drug semaglutide had fewer problems with urinary retention and urinary‑tract infections than those who didn’t take the drug. The benefit seemed to go beyond just losing weight, suggesting semaglutide might help the bladder recover better after Botox. The research was retrospective and matched patients for age, race, blood pressure and body‑mass index, so it’s not a definitive proof but points to a possible added advantage.
Nowak. Klaudia K; Dziewierz. Artur A; Sojda. Aleksandra A; Zabojszcz. Michał M; Szarpak. ...
In Poland, use of GLP‑1 drugs exploded from a few hundred to over 12,000 patients between 2018 and 2024, mainly for obesity. The oral pill form of semaglutide grew fast and made up half of all semaglutide prescriptions in 2024, especially among younger women with fewer health problems, showing it’s a practical, non‑injectable option for weight‑loss‑focused biohackers.
Wang. Xinye X; Wang. Xiaoting X; Zhuang. Hong H; Lu. Guangzhen G; Zhao. Gang G
In diabetic mice, giving semaglutide for 8 weeks helped keep tiny heart blood vessels healthy. It fixed vessel structure, reduced scar tissue around vessels, and lowered inflammation, oxidative stress, and cell death. These benefits were linked to several molecular pathways that semaglutide turned on or off.
Saleem. Noor Ul Ain NUA; Khan. Mishaim M; Tague. Christian C; Akilimali. Aymar A
A recent look at semaglutide (Ozempic/Wegovy) shows that while it helps lower blood sugar and cut weight, it may also raise the chance of a serious eye problem called non‑arteritic anterior ischemic optic neuropathy (NAION), with about 6‑9% of users experiencing it in studies.
Dauleh. Hajar H; Mohammed. Idris I; Hussain. Khalid K
In two kids with rare genetic disorders that cause severe obesity and insulin resistance, the diabetes drug semaglutide (a GLP‑1 receptor agonist) led to big improvements in weight and blood‑sugar control. This hints that semaglutide might help people whose obesity stems from messed‑up leptin or insulin signaling, even if they don’t have the usual type‑2 diabetes.
Hirai. Taro T; Kitada. Munehiro M; Endo. Keita K; Hayashi. Koichi K; Suzuki. Toshihiko T
A 23‑year‑old woman with slowly progressive type 1 diabetes (a form of LADA) struggled to control blood sugar and weight despite insulin, dapagliflozin, and metformin. When she started taking oral semaglutide, her blood sugar dropped, she lost weight, and she could stop insulin. She also reported healthier eating habits after starting the drug.
This review looks at what we know about using the weight‑loss drug semaglutide (Ozempic) during pregnancy. It isn’t approved for pregnant women, but more women of child‑bearing age are taking it, leading to accidental exposures. Animal studies show it can affect fetal growth, while early human case reports haven’t found clear harm, but data are still very limited.